These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34345182)

  • 1. Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19.
    Dreyer N; Petruski-Ivleva N; Albert L; Mohamed D; Brinkley E; Reynolds M; Toovey S
    Int J Gen Med; 2021; 14():3941-3949. PubMed ID: 34345182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The other COVID-19 survivors: Timing, duration, and health impact of post-acute sequelae of SARS-CoV-2 infection.
    Lambert N; ; El-Azab SA; Ramrakhiani NS; Barisano A; Yu L; Taylor K; Esperança Á; Mendiola C; Downs CA; Abrahim HL; Hughes T; Rahmani AM; Borelli JL; Chakraborty R; Pinto MD
    J Clin Nurs; 2024 Jan; 33(1):76-88. PubMed ID: 36181315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
    Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
    LaVergne SM; Stromberg S; Baxter BA; Webb TL; Dutt TS; Berry K; Tipton M; Haberman J; Massey BR; McFann K; Alnachoukati O; Zier L; Heacock T; Ebel GD; Henao-Tamayo M; Dunn J; Ryan EP
    BMC Infect Dis; 2021 Jul; 21(1):677. PubMed ID: 34256735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and determinants of post-acute sequelae of COVID-19 in Liberia.
    Gwaikolo C; Sackie-Wapoe Y; Badio M; Glidden DV; Lindan C; Martin J
    Int J Epidemiol; 2024 Feb; 53(1):. PubMed ID: 38052015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings.
    Sneller MC; Liang CJ; Marques AR; Chung JY; Shanbhag SM; Fontana JR; Raza H; Okeke O; Dewar RL; Higgins BP; Tolstenko K; Kwan RW; Gittens KR; Seamon CA; McCormack G; Shaw JS; Okpali GM; Law M; Trihemasava K; Kennedy BD; Shi V; Justement JS; Buckner CM; Blazkova J; Moir S; Chun TW; Lane HC
    Ann Intern Med; 2022 Jul; 175(7):969-979. PubMed ID: 35605238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases.
    Patel NJ; Cook C; Vanni K; Fu X; Wang X; Kawano Y; Qian G; Hang B; Srivatsan S; Banasiak EP; Kowalski E; Bade K; Zhang Y; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2023 Apr; 82(4):565-573. PubMed ID: 36442978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between SARS-CoV-2 Infection and Select Symptoms and Conditions 31 to 150 Days After Testing among Children and Adults.
    Zhang Y; Romieu-Hernandez A; Boehmer TK; Azziz-Baumgartner E; Carton TW; Gundlapalli AV; Fearrington J; Nagavedu K; Dea K; Moyneur E; Cowell LG; Kaushal R; Mayer KH; Puro J; Rasmussen SA; Thacker D; Weiner MG; Saydeh S; Block JP;
    medRxiv; 2022 Dec; ():. PubMed ID: 36597540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents: an exploratory EHR-based cohort study from the RECOVER program.
    Rao S; Lee GM; Razzaghi H; Lorman V; Mejias A; Pajor NM; Thacker D; Webb R; Dickinson K; Bailey LC; Jhaveri R; Christakis DA; Bennett TD; Chen Y; Forrest CB
    medRxiv; 2022 May; ():. PubMed ID: 35665016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study.
    Venkat RK; Wang X; Patel NJ; Kawano Y; Schiff A; Kowalski EN; Cook CE; Vanni KMM; Qian G; Bade KJ; Saavedra A; Srivatsan S; Williams ZK; Wallace ZS; Sparks JA
    Rheumatology (Oxford); 2024 Oct; 63(10):2828-2837. PubMed ID: 38070152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Disease Self-Management of Post-Acute Sequelae of COVID-19 Among Older Adults: A Mixed-Methods Analysis.
    Thomas-Purcell K; Davenport R; Ayala V; Purcell D; Ownby RL
    Clin Interv Aging; 2023; 18():607-617. PubMed ID: 37082741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence.
    Visvabharathy L; Orban ZS; Koralnik IJ
    Front Med (Lausanne); 2022; 9():1003103. PubMed ID: 36213654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Living like an empty gas tank with a leak": Mixed methods study on post-acute sequelae of COVID-19.
    Ogungbe O; Slone S; Alharthi A; Tomiwa T; Kumbe B; Bergman A; McNabb K; Smith Wright R; Farley JE; Dennison Himmelfarb CR; Cooper LA; Post WS; Davidson PM; Commodore-Mensah Y
    PLoS One; 2022; 17(12):e0279684. PubMed ID: 36584125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.